| Not Yet Recruiting | Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasop NCT07524413 | Sun Yat-sen University | Phase 3 |
| Not Yet Recruiting | Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma NCT07385079 | Sun Yat-sen University | Phase 3 |
| Not Yet Recruiting | Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma NCT07373990 | Sun Yat-sen University | Phase 3 |
| Recruiting | QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carc NCT06749899 | Sun Yat-Sen University Cancer Center | Phase 3 |
| Recruiting | Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma NCT06682442 | University of California, San Francisco | N/A |
| Recruiting | Trop2-targeted immunoPET Imaging of Solid Tumors NCT06851663 | RenJi Hospital | Phase 2 / Phase 3 |
| Not Yet Recruiting | Exploratory Study of EBV DNA Titre Clearance Whilst on Proton Beam Therapy NCT06480903 | The Christie NHS Foundation Trust | — |
| Recruiting | Adebrelimab and Chemoradiotherapy in High-risk LANPC NCT06349889 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Ca NCT06414577 | XIANG YANQUN | Phase 2 |
| Completed | 68Ga-FAPI-46 PET/CT for the Prediction of Clinical Response to Neoadjuvant Therapy in Nasopharyngeal Carcinoma NCT07139054 | The First Affiliated Hospital of Xiamen University | — |
| Recruiting | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Sol NCT05983432 | SystImmune Inc. | Phase 1 |
| Active Not Recruiting | Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE) NCT05587374 | Sun Yat-sen University | Phase 3 |
| Recruiting | Arabic PRO Measures for Head and Neck Cancer Radiotherapy. NCT06662929 | King Saud University | — |
| Recruiting | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma NCT06019130 | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Phase 2 |
| Recruiting | Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT NCT05628922 | Fudan University | Phase 2 |
| Active Not Recruiting | Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer NCT05261750 | PT. Prodia Stem Cell Indonesia | Phase 1 / Phase 2 |
| Terminated | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tu NCT05070247 | Takeda | Phase 1 / Phase 2 |
| Recruiting | Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevac NCT05305131 | National University Hospital, Singapore | Phase 2 |
| Recruiting | A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China NCT05638269 | Zhujiang Hospital | — |
| Active Not Recruiting | P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors NCT05239143 | Poseida Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharynge NCT04925544 | Stanford University | Phase 2 |
| Recruiting | Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment NCT04875611 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 |
| Unknown | Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy NCT04978012 | Fudan University | Phase 2 |
| Completed | Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer NCT05564286 | Shantou University Medical College | Phase 3 |
| Unknown | Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study NCT04850235 | Sun Yat-sen University | Phase 1 |
| Recruiting | Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma NCT04453826 | Sun Yat-sen University | Phase 3 |
| Completed | Somatostatin Receptor Imaging in NPC, EBV Related Cancers NCT05581550 | National Cancer Centre, Singapore | N/A |
| Unknown | Applying PET/MR in Oncology - a Prospective Project NCT04158414 | Tel-Aviv Sourasky Medical Center | N/A |
| Terminated | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) NCT03682055 | Cullinan Therapeutics Inc. | Phase 1 / Phase 2 |
| Completed | Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyng NCT04004871 | Guangxi Medical University | Phase 2 |
| Recruiting | The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma NCT06268600 | Jiangxi Provincial Cancer Hospital | N/A |
| Completed | Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI NCT03656250 | NYU Langone Health | — |
| Unknown | Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nas NCT03282617 | National University Hospital, Singapore | Phase 1 |
| Terminated | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma a NCT03144661 | Incyte Corporation | Phase 1 |
| Unknown | A Study of Nasopharyngeal Carcinoma From Guangdong NCT03003182 | Sun Yat-sen University | — |
| Unknown | Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions NCT03129412 | Zhejiang Cancer Hospital | Phase 2 |
| Unknown | Cell-free Tumor DNA in Head and Neck Cancer Patients NCT03942380 | Christian von Buchwald | N/A |
| Terminated | Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer NCT02875613 | Assuntina Sacco, M.D. | Phase 2 |
| Unknown | A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors NCT04476641 | Sun Yat-sen University | Phase 2 |
| Recruiting | Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients NCT04340024 | National Cancer Centre, Singapore | — |
| Unknown | Reactivating NK Cells in Treating Refractory Head and Neck Cancer NCT02507154 | National University Hospital, Singapore | Phase 1 / Phase 2 |
| Terminated | Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors NCT02080416 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Recruiting | Integrated Cancer Repository for Cancer Research NCT02012699 | University of Nebraska | — |
| Completed | A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma NCT01800071 | Cancer Research UK | Phase 1 |
| Completed | Swallowing Exercises for Nasopharyngeal Cancer After Radiation Therapy NCT01937793 | National Taiwan University Hospital | N/A |
| Unknown | Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC NCT03890185 | King Faisal Specialist Hospital & Research Center | Phase 2 |
| Completed | Assessment of New Radiation Oncology Technologies and Treatments NCT01379872 | Trans Tasman Radiation Oncology Group | — |
| Unknown | Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultr NCT01347424 | Sun Yat-sen University | Phase 2 |
| Completed | 124I-FIAU Imaging in EBV and KSHV Associated Cancers NCT00982449 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Completed | Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residu NCT01094405 | Chinese University of Hong Kong | Phase 2 |
| Unknown | Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer NCT01074021 | Biotech Pharmaceutical Co., Ltd. | Phase 3 |
| Unknown | A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer NCT00943891 | National University Hospital, Singapore | — |
| Unknown | Cluster Randomized Controlled Screening Trial for NPC NCT00941538 | Sun Yat-sen University | N/A |
| Completed | Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygn NCT00706316 | University Health Network, Toronto | Phase 1 |
| Completed | A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasophary NCT00439426 | Hoffmann-La Roche | Phase 2 |
| Completed | Acupuncture for Prevention of Radiation-Induced Xerostomia NCT00430378 | M.D. Anderson Cancer Center | N/A |
| Completed | A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) D NCT00370890 | Chinese University of Hong Kong | Phase 3 |
| Unknown | Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer NCT01312311 | Samsung Medical Center | Phase 2 |
| Completed | A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer NCT00603915 | University Health Network, Toronto | Phase 2 |
| Unknown | Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients NCT00304694 | National Taiwan University Hospital | — |
| Completed | To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal C NCT00697619 | Sun Yat-sen University | Phase 2 |
| Completed | A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Can NCT02608073 | Hoffmann-La Roche | Phase 2 |
| Completed | EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma NCT00078546 | Baylor College of Medicine | Phase 1 |
| Completed | Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma NCT03175939 | Sun Yat-sen University | Phase 2 |
| Completed | Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers NCT00141765 | University of Michigan Rogel Cancer Center | Phase 2 |